Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  28 (2024)
Volume  27 (2023)
Volume  26 (2022)
Volume  25 (2021)
Volume  24 (2020)
Volume  23 (2019)
Volume  22 (2018)
Volume  21 (2017)
Volume  20 (2016)
Volume  19 (2015)
Volume  18 (2014)
Volume  17 (2013)
Volume  16 (2012)
Volume  15 (2011)
Volume  14 (2010)
Volume  13 (2009)
Volume  12 (2008)
Volume  11 (2007)
Volume  10 (2006)
Volume  9 (2005)
Volume  8 (2004)
Related articles

VOLUME 28 , ISSUE 10 ( October, 2024 ) > List of Articles

Original Article

Respiratory Complications in the Immediate Postoperative Period after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Nowadays: An Observational Study

Maria-Consuelo Pintado, Ana Oñoro, Diego Beltran, Emilio Nevado

Keywords : Cytoreductive surgery, Hyperthermic intraperitoneal chemotherapy, Peritoneal carcinomatosis, Prognosis, Respiratory complications

Citation Information : Pintado M, Oñoro A, Beltran D, Nevado E. Respiratory Complications in the Immediate Postoperative Period after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Nowadays: An Observational Study. Indian J Crit Care Med 2024; 28 (10):952-957.

DOI: 10.5005/jp-journals-10071-24810

License: CC BY-NC 4.0

Published Online: 30-09-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Background and objectives: Several respiratory complications have been described after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Materials and methods: Patients admitted to intensive care unit (ICU) after CRS and HIPEC during 10 years. Data recorded were: Demographic characteristics; severity of illness; complete blood sample; chest radiographs; type of cancer and extension; HIPEC drug and temperature; ICU and hospital stay; and mortality. Results: Of the 124 patients included, 67 patients (54.0%) presented respiratory complications: 56 (83.6%) acute respiratory failure, 25 (37.3%) pleural effusion, 13 (19.4%) atelectasis, and 3 (4.5%) other; only 1 (3.0%) developed pneumonia. They had higher severity scores at ICU admission. 1 patient required initiation of invasive mechanical ventilation during ICU admission due to pneumonia, and 1 patient needed placement of a pleural chest tube due to symptomatic pleural effusion. Only the need for a high fluid balance during surgery was correlated to the development of respiratory complications on multivariate analysis. Median ICU stay was 5 (4.0–5.0) days. ICU mortality was 0.8.0%. Conclusion: In our study, 54% of patients treated with CRS and HIPEC developed respiratory complications during the postoperative period. However, the majority of these complications were not severe and did not significantly impact mortality rates or hospital stays.

PDF Share
  1. Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 1998;14(3):254–261. DOI: 10.1002/(sici)1098-2388(199804/05)14:3<254::aid-ssu10>3.0.co;2-u.
  2. Glockzin G, Schlitt HJ, Piso P. Peritoneal carcinomatosis: Patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 2009;7:5. DOI: 10.1186/1477-7819-7-5.
  3. Cascales Campos P, Martinez Insfran LA, Wallace D, Gil J, Gil E, Gonzalez Gil A, et al. Identifying the incidence of respiratory complications following diaphragmatic cytoreduction and hyperthermic intraoperative intraperitoneal chemotherapy. Clin Transl Oncol 2020;22(6):852–859. DOI: 10.1007/s12094-019-02195-8.
  4. Ramos Bernado MI, Crusellas Mana O, Martin-Baranera M, Barrios Sanchez P. Morbimortality after 1321 consecutive CRS + HIPEC procedures: Seeking excellence in surgery for peritoneal surface malignancy. Clin Transl Oncol 2023;25(10):2911–2921. DOI: 10.1007/s12094-023-03155-z.
  5. Alonso O, Sugarbaker PH. Adult respiratory distress syndrome occurring in two patients undergoing cytoreductive surgery plus perioperative intraperitoneal chemotherapy: Case reports and a review of the literature. Am Surg 2000;66(11):1032–1036. PMID: 11090013.
  6. Sinukumar S, Mehta S, Damodaran D, Rajan F, Zaveri S, Ray M, et al. Failure-to-rescue following cytoreductive surgery with or without HIPEC is determined by the type of complication-a retrospective study by INDEPSO. Indian J Surg Oncol 2019;10(Suppl 1):71–79. DOI: 10.1007/s13193-019-00877-x.
  7. Arakelian E, Torkzad MR, Bergman A, Rubertsson S, Mahteme H. Pulmonary influences on early post-operative recovery in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy treatment: A retrospective study. World J Surg Oncol 2012;10:258. DOI: 10.1186/1477-7819-10-258.
  8. Padmakumar AV. Intensive care management of patient after cytoreductive surgery and hIPEC – A concise review. Indian J Surg Oncol 2016;7(2):244–248. DOI: 10.1007/s13193-016-0511-7.
  9. Preti V, Chang D, Sugarbaker PH. Pulmonary complications following cytoreductive surgery and perioperative chemotherapy in 147 consecutive patients. Gastroenterol Res Pract 2012;2012:635314. DOI: 10.1155/2012/635314.
  10. Kusamura S, Younan R, Baratti D, Costanzo P, Favaro M, Gavazzi C, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: Analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer 2006;106(5):1144–1153. DOI: 10.1002/cncr.21708.
  11. Sand O, Andersson M, Arakelian E, Cashin P, Semenas E, Graf W. Severe pulmonary complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy are common and contribute to decreased overall survival. PLoS One 2021;16(12):e0261852. DOI: 10.1371/journal.pone.0261852.
  12. Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: A systematic review of morbidity and mortality. Ann Surg 2009;249(6):900–907. DOI: 10.1097/SLA.0b013e3181a45d86.
  13. Navarro Santana B, Garcia-Torralba E, Viveros-Carreno D, Rodriguez J, Pareja R, Martin A, et al. Complications of HIPEC for ovarian cancer surgery: Evaluation over two time periods. Int J Gynecol Cancer 2023;ijgc-2023-004658. DOI: 10.1136/ijgc-2023-004658.
  14. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of disease classification system. Crit Care Med 1985;13(10): 818–829.
  15. Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: Results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med 1998;26(11):1793–1800. DOI: 10.1097/00003246-199811000-00016.
  16. Zhou S, Feng Q, Zhang J, Zhou H, Jiang Z, Liu Z, et al. High-grade postoperative complications affect survival outcomes of patients with colorectal cancer peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. BMC Cancer 2021;21(1):41. DOI: 10.1186/s12885-020-07756-7.
  17. U.S. Department of Health and Human Services. National Institute of Heatlh. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 2009. Available from: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf.
  18. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–213. DOI: 10.1097/01.sla.0000133083.54934.ae.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.